LJPC-401 for myocardial iron overload in transfusion-dependent beta thalassemia

Phase 2, randomised, open-label trial in beta thalassemia and iron overload cardiomyopathy (IOC) comparing Standard of care with LJPC-401 plus standard of care (2 arms). Primary endpoint: Mean change from baseline in cardiac iron by T2* MRI at 26 weeks. Status: unknown.